Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 443 across all filing types
Latest filing 2020-03-04 Regulatory Filings
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1479 characters) and contains an 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Price Monitoring Extension' for a security, which is a specific, non-standard market operational announcement. It does not appear to be a core financial report (like 10-K, IR, ER) or a standard corporate action announcement (like DIV, CAP). Given that it is a specific, non-standard regulatory update disseminated via the RNS system, and it doesn't fit any other specific category, the most appropriate classification is the general regulatory filing fallback category.
2020-03-04 English
Incanthera plc – Admission to trading on NEX
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated February 28, 2020. It announces that Incanthera plc has been admitted to trading on the NEX Exchange Growth Market and has 'published its Admission Document'. The text is short (under 5,000 characters) and serves primarily to notify the market about the publication of another company's admission document and the resulting shareholding structure for ImmuPharma. The presence of 'RNS Number' and the concluding statement about RNS being the news service of the London Stock Exchange strongly suggest a regulatory news service announcement. Since the core purpose is announcing the publication of a document (Admission Document) rather than being the document itself, and it fits the general regulatory announcement structure, it aligns best with the Regulatory Filings (RNS) category, which serves as a general regulatory announcement fallback.
2020-02-28 English
Incanthera plc – Admission to trading on the NEX Exchange Growth Market Publication of Admission Document
Share Issue/Capital Change Classification · 1% confidence The document is an announcement by ImmuPharma PLC noting that another company, Incanthera plc, has been admitted to trading on the NEX Exchange Growth Market and has published its Admission Document. The text details ImmuPharma's resulting shareholding, warrants, and subscription rights related to Incanthera's listing. This is not a primary financial report (like 10-K or IR), nor is it a standard earnings release (ER) or a formal proxy statement. It is a specific corporate action announcement concerning an investment/transaction in another entity, which is best categorized as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) due to the subscription rights mentioned. Given the focus is on the admission and the resulting share structure, and it doesn't fit the specific definitions for M&A (TAR) or Share Issue (SHA) for ImmuPharma itself, RNS serves as the most appropriate general regulatory announcement category for this type of market update.
2020-02-28 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1482 characters) and contains an 'RNS Number' header, indicating it is a regulatory news service announcement from the London Stock Exchange. The content discusses a 'Price Monitoring Extension' for a security, which is a specific, short-form operational update related to trading mechanisms, not a comprehensive financial report (like 10-K or IR) or a standard announcement of a report (like RPA). Since it is a specific regulatory announcement that doesn't fit the other detailed categories (like DIRS, DIV, ER, etc.), the most appropriate classification is the general regulatory filing fallback category, RNS.
2020-02-21 English
Incanthera announces Rule 23 Notice re NEX listing
Regulatory Filings Classification · 1% confidence The document is identified by the header 'RNS Number : 1304D' and concludes with standard disclaimers referencing 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content announces an event related to another company (Incanthera plc) seeking a quote on the NEX Exchange, which is a regulatory notification concerning shareholdings and warrants. This type of general, time-sensitive regulatory announcement that doesn't fit a specific financial report category (like 10-K, ER, or IR) is best classified as a general Regulatory Filing, which corresponds to the RNS code.
2020-02-17 English
Oncology specialist Incanthera, in which ImmuPharma currently has a 14.0% shareholding, announces Rule 23 Notice in advance to quoting on NEX Exchange Growth Market
Regulatory Filings Classification · 1% confidence The document is an announcement by ImmuPharma PLC regarding another company, Incanthera plc, which is preparing to list on the NEX Exchange Growth Market. The text details ImmuPharma's existing shareholding and warrants in Incanthera and quotes the CEO's reaction. This type of announcement, which reports on the corporate activities or market movements of another entity in which the reporting company has a significant stake, does not fit neatly into the primary financial reporting categories (10-K, IR, ER, etc.). It is a general corporate update concerning market activity and shareholdings. Since it is not a Director's Dealing (DIRS), a Major Shareholding Notification (MRQ - which usually reports crossing a threshold), or a formal M&A activity (TAR), the most appropriate fallback category is Regulatory Filings (RNS) for miscellaneous regulatory announcements that convey material, non-standard corporate news.
2020-02-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.